Claire K Hoy, Somanathapura K NaveenKumar, Sherwin A Navaz, Kavya Sugur, Srilakshmi Yalavarthi, Cyrus Sarosh, Tristin Smith, Katarina Kmetova, Emily Chong, Noah F Peters, Christine E Rysenga, Gary L Norman, Gabriel Figueroa-Parra, Dava Nelson, Jennifer Girard, Asra Z Ahmed, Jordan K Schaefer, Johann E Gudjonsson, J Michelle Kahlenberg, Jacqueline A Madison, Jason S Knight, Cynthia S Crowson, Alí Duarte-García, Yu Zuo
OBJECTIVE: While thrombosis and pregnancy loss are the best-known clinical features of antiphospholipid syndrome (APS), many patients also exhibit "extra-criteria" manifestations, like thrombocytopenia. The mechanisms that drive APS thrombocytopenia are not completely understood, and no clinical biomarkers are available for predicting antiphospholipid antibody (aPL)-mediated thrombocytopenia. Calprotectin is a heterodimer of S100A8 and S100A9 that is abundant in the neutrophil cytoplasm and released upon proinflammatory neutrophil activation...
January 16, 2024: Arthritis & Rheumatology